Clinical Trial Update: Yizhi Baduanjin for Patients With Cognitive Impairment [NA]

View source ↗

Summary

A clinical trial investigating Yizhi Baduanjin for mild cognitive impairment has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Snippet

Sponsor: The University of Hong Kong | Conditions: Mild Cognitive Impairment (MCI) | NA | Status: TERMINATED